PUBLISHER: SkyQuest | PRODUCT CODE: 1448368
PUBLISHER: SkyQuest | PRODUCT CODE: 1448368
Global Anterior Uveitis Treatment Market Size, Share, Growth Analysis, By Treatment(Corticosteroids, Cycloplegic Agents), By Distribution Channel(Hospital, Retail) - Industry Forecast 2024-2031
Global Anterior Uveitis Treatment Market size was valued at USD 350 million in 2022 and is poised to grow from USD 371 billion in 2023 to USD 591.32 billion by 2031, growing at a CAGR of 6% during the forecast period (2024-2031).
The surge in cases of anterior uveitis is a significant driving force behind its expansion, characterized by inflammation in the front portion of the eye's uvea. Management primarily involves corticosteroids and immunosuppressive agents, often administered through corticosteroid eye drops. Various underlying conditions can trigger anterior uveitis, contributing to its prevalence. Prescription of corticosteroids is contingent upon the type of uveitis due to their impact on the immune system. With an aging global population, the vulnerability to this condition increases. Innovations in treatments, exemplified by Humira's approval, are expected to fuel growth, alongside factors such as heightened awareness, ocular infection rates, and favorable regulatory environments. Complications associated with anterior uveitis include elevated intraocular pressure and potential adverse reactions to corticosteroid treatment, leading to conditions like glaucoma and cataracts, emphasizing the need for effective management strategies to prevent irreversible blindness.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anterior Uveitis Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Anterior Uveitis Treatment Market Segmental Analysis
The global anterior uveitis treatment market is segmented on the basis of treatment, distribution channel, region. By treatment, the market is segmented into corticosteroids, cycloplegic agents, anti-tnf agents, immunosuppressants. By distribution channel, the market is segmented into hospital, retail, online pharmacies. By region, the market is segmented into North America, Europe, Latin America, Asia- Pacific, Middle East and Africa.
Drivers of the Global Anterior Uveitis Treatment Market
The rising prevalence of anterior uveitis worldwide, along with the expanding elderly population, serves as a key factor propelling market growth. With the disease becoming more widespread, there is a heightened demand for efficient treatment options.
Restraints in the Global Anterior Uveitis Treatment Market
Certain treatment methods, notably corticosteroids, have the potential to induce undesirable outcomes such as elevated intraocular pressure, cataracts, and glaucoma, which can constrain their prolonged application and impact patient adherence.
Market Trends of the Global Anterior Uveitis Treatment Market
Exploring gene therapies offers hope in tackling the underlying triggers of anterior uveitis through the precise targeting of particular genetic mutations or irregularities linked to this condition.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Anterior Uveitis Treatment Market by Treatment
- Market Overview
- Corticosteroids
- Cycloplegic Agents
- Anti-TNF Agents
- Immunosuppressants
Global Anterior Uveitis Treatment Market by Distribution Channel
- Market Overview
- Hospital
- Retail
- Online Pharmacies
Global Anterior Uveitis Treatment Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Allergan (now part of AbbVie Inc.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bausch Health Companies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Santen Pharmaceutical Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alcon Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- EyePoint Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Valeant Pharmaceuticals International (now Bausch Health Companies Inc.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bausch Health Companies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mylan N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Akorn Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ocular Therapeutix, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Clearside Biomedical, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Topcon Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Carl Zeiss Meditec AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
